Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Retrospective Analysis of the Outcome of Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) Included in a Patient Named Program of Gemtuzumab Ozogamicin/Mylotarg®

NCT03287128 is registered in ClinicalTrials.gov with Versailles Hospital as lead sponsor.

NCT NCT03287128
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03287128 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Retrospective Analysis of the Outcome of Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) Included in a Patient Named Program of Gemtuzumab Ozogamicin/Mylotarg®
Lead sponsor
Versailles Hospital
Phase
Observational
Overall status
Unknown status
Start date
November 1, 2017
Completion date
March 1, 2019
Enrollment
300 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, myeloid, acute